186521-98-2

Basic information

• Product Name: (3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE
• Synonyms: N-ALPHA-TERT-BUTYLOXYCARBONYL-L-ALANINYL-DIAZOMETHANE;BOC-L-ALA-CHN2;(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE
• CAS NO: 186521-98-2
• Molecular Formula: C₉H₁₅N₃O₃
• Molecular Weight: 213.23
• Mol File: 186521-98-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE(186521-98-2)
• EPA Substance Registry System: (3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE(186521-98-2)

Safety Data

• Hazardous Substances Data: 186521-98-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE is used as a reagent for the introduction of an amino group into organic molecules, which is crucial for the synthesis of various organic compounds.
Used in Biomolecule Modification:
(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE is used as a modifying agent for biomolecules, enabling the attachment of an amino group to these molecules, which can be particularly useful in the development of new pharmaceuticals.
Used in Pharmaceutical Synthesis:
(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE is used as an intermediate in the synthesis of pharmaceuticals, where the BOC-protected amine can be deprotected to facilitate the formation of the desired drug molecules.
Used in Chemical Transformations:
(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE is used as a versatile intermediate for various chemical transformations, such as cyclopropanation and aziridination, which are important reactions in the field of organic chemistry.
Used in Research and Development:
(3S)-3-BOC-AMINO-1-DIAZO-2-BUTANONE is used in research and development for exploring new synthetic pathways and developing innovative applications in the chemical and pharmaceutical industries.

Upstream product

• 186581-53-3 diazomethane 
• 954143-61-4 (R)-2-tert-butoxycarbonylaminopropionyl chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3744-87-4 Boc-(R)-Ala 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 497861-77-5 (+)-tert-butyl [(R)-1-methyl-3-oxopropyl]carbamate 
• 193152-95-3 (2R,3R)-3-tert-Butoxycarbonylamino-2-(3-cyano-benzyl)-butyric acid methyl ester 
• 159877-47-1 methyl 3-(R)-[N-(tert-butoxycarbonyl)amino]-propanoate 
• 159991-23-8 (R)-3-((tert-butoxycarbonyl)amino)butanoic acid 

Relevant articles and documents

Total synthesis of (-)-epimyrtine by a gold-catalyzed hydroamination approach

A new approach to the total synthesis of (-)-epimyrtine has been developed from D-alanine. The key step to access the enantiopure pyridone intermediate was achieved by a gold-mediated cyclization. Finally, various transformations afforded the natural prod

Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- And C-Methylations Fine-Tune Conformation and Properties

Incorporating small modifications to peptidic macrocycles can have a major influence on their properties. For instance, N-methylation has been shown to impact permeability. A better understanding of the relationship between permeability and structure is of key importance as peptidic drugs are often associated with unfavorable pharmacokinetic profiles. Starting from a semipeptidic macrocycle backbone composed of a tripeptide tethered head-to-tail with an alkyl linker, we investigated two small changes: peptide-to-peptoid substitution and various methyl placements on the nonpeptidic linker. Implementing these changes in parallel, we created a collection of 36 compounds. Their permeability was then assessed in parallel artificial membrane permeability assay (PAMPA) and Caco-2 assays. Our results show a systematic improvement in permeability associated with one peptoid position in the cycle, while the influence of methyl substitution varies on a case-by-case basis. Using a combination of molecular dynamics simulations and NMR measurements, we offer hypotheses to explain such behavior.

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.

PYRAZOLYL DERIVATIVES AS SYK INHIBITORS

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

TAPP analogs containing β3-homo-amino acids: Synthesis and receptor binding

β-Amino acids containing α,β-hybrid peptides show great potential as peptidomimetics. In this paper, we describe the synthesis and affinity to μ-opioid and δ-opioid receptors of α,β-hybrids, analogs of the tetrapeptide Tyr- d-Ala-Phe-Phe-NH2 (TAPP). Each amino acid was replaced with an l- or d-β3-h-amino acid. All α,β-hybrids of TAPP analogs were synthesized in solution and tested for affinity to μ-opioid and δ-opioid receptors. The analog Tyr-β3h- d-Ala-Phe-PheNH2 was found to be as active as the native tetrapeptide.

Enantiospecific synthesis of pyridinones as versatile intermediates toward asymmetric piperidines

The enantiospecific syntheses of pyridinones from amino acids via a gold-catalyzed strategy are reported. Excellent stereocontrol was observed during the cyclization. This approach provides a straightforward tool for further synthetic applications toward

Optimization of the β-aminoester class of factor Xa inhibitors. Part 1: P4 and side-chain modifications for improved in vitro potency

A systematic modification of the C3 side-chain of the β-aminoester class of factor Xa inhibitors and a survey of P4 variations is described. These changes have resulted in the identification of sub-nanomolar inhibitors with improved selectivity versus related proteases. Coagulation parameters (i.e., APTT doubling concentrations) are also improved.